US74587V1070
© BusinessWire
22.12.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025.
“Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitabilit...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee.
The award was granted under Puma’s 2017 Empl...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 11,250 shares of Puma common stock to two new non-executive employees.
The awards were granted under Puma’s 2017 Em...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
06.11.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Third Quarter 2025 Financial Results
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2025. Unless otherwise stated, all comparisons are for the third quarter of 2025 compared to the third quarter of 2024.
Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma’s first comm...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
23.10.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, Nov. 6, 2025, following the release of its third quarter 2025 financial results.
The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 mi...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 9,375 shares of Puma common stock to one new non-executive employee.
The award was granted under Puma’s 2017 Empl...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that on September 2, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 25,750 shares of Puma common stock to four new non-executive employees.
The awards were granted under Puma’s 2017...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 1:00 p.m. EDT on Monday, September 8, at the H.C. Wainwright 27th Annual Global Investment Conference. The conference will be held Septem...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, August 7, 2025, following the release of its second quarter 2025 financial results.
The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10...
Themefolio
Profiler
Peergroup
© BusinessWire
02.07.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 7,000 shares of Puma common stock to two new non-executive employees.
The awards were granted under Puma’s 2017 Employ...
Themefolio
Profiler
Peergroup
© BusinessWire
04.06.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 18,250 shares of Puma common stock to three new non-executive employees.
The awards were granted under Puma’s 2017 Emp...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports First Quarter Financial Results
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024.
Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first comme...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
06.05.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 12,875 shares of Puma common stock to two new non-executive employees.
The awards were granted under Puma’s 2017 Employm...
Themefolio
Profiler
Peergroup
© BusinessWire
28.04.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR Annual Meeting is currently taking place at the McCormick Place in Chicago, Illinois. The poster is entitled, “CT071:...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 8, 2025, following the release of its first quarter 2025 financial results.
The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minu...
Themefolio
Profiler
Peergroup
© BusinessWire
02.04.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 23,875 shares of Puma common stock to four new non-executive employees.
The awards were granted under Puma’s 2017 Empl...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that clinical data on neratinib will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR Annual Meeting will be held at the McCormick Place in Chicago, Illinois, from April 25–30, 2025. The title of the poster that will be...
Themefolio
Profiler
Peergroup
© BusinessWire
06.03.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee.
The award was granted under Puma’s 2017 Employm...
Themefolio
Profiler
Peergroup
© BusinessWire
05.03.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on Tuesday, March 11, at Barclays 27th Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach.
A live w...
Themefolio
Profiler
Peergroup
© BusinessWire
05.03.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on Tuesday, March 11, at Barclays 27th Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach.
A live w...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the fourth quarter and full year 2023.
Product revenue, net consists entirely of revenue from...
Themefolio
Profiler
Peergroup
© BusinessWire
26.02.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 11:10 a.m. ET on Wednesday, March 5, at the TD Cowen 45th Annual Health Care Conference. The conference will be held March 3–5, 2025 at the Boston Marri...
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 27, 2025, following the release of its fourth quarter and full year 2024 financial results.
The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please di...
Themefolio
Profiler
Peergroup
© BusinessWire
05.02.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 7,250 shares of Puma common stock to two new non-executive employees.
The awards were granted under Puma’s 2017 Em...
Themefolio
Profiler
Peergroup
© BusinessWire
03.01.2025
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 2, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 24,375 shares of Puma common stock to two new non-executive employees.
The awards were granted under Puma’s 2017 Em...
Themefolio
Profiler
Peergroup
© BusinessWire
23.12.2024
PBYI
LISTED
NASDAQ
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cervical Cancer were updated to include an addition involving neratinib (NERLYNX®).
The updated NCCN Practice Guidelines for Cervical Cancer include...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 2, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 7,500 shares of Puma common stock to one new non-executive employee.
The award was granted under Puma’s 2017 Emp...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2024
PBYI
LISTED
NASDAQ
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA™-Breast1) Phase II trial (PUMA-ALI-1201; NCT06369285) of alisertib in combination with endocrine therapy for the treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negat...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Third Quarter 2024 Financial Results
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2024. Unless otherwise stated, all comparisons are for the third quarter of 2024 compared to the third quarter of 2023.
Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma’s first comm...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
PBYI
LISTED
NASDAQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 4, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 5,625 shares of Puma common stock to one new non-executive employee.
The award was granted under Puma’s 2017 Empl...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
PBYI
LISTED
NASDAQ
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
News Preview
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, November 7, 2024, following the release of its third quarter 2024 financial results.
The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 1...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2024
PBYI
LISTED
NASDAQ
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
News Preview
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of the Company at 3:00 p.m. EDT on Monday, September 9 at the H.C. Wainwright 26th Annual Global Investment Conference. The conference will be held September 9 – 1...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
